Stereotaxis
STXS
93 hedge funds and large institutions have $149M invested in Stereotaxis in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 36 reducing their positions, and 16 closing their positions.
995% more call options, than puts
Call options by funds: $657K | Put options by funds: $60K
3.09% less ownership
Funds ownership: 56.98% → 53.89% (-3.1%)
4% less funds holding
Funds holding: 97 → 93 (-4)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
33% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 36
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
43% less capital invested
Capital invested by funds: $263M → $149M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lagoda Investment Management
New York
|
+$892K |
| 2 |
HM
HealthCor Management
New York
|
+$780K |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$598K |
| 4 |
PGM
Parian Global Management
Pound Ridge,
New York
|
+$584K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.56M |
| 2 |
KLC
Kent Lake Capital
Reno,
Nevada
|
-$2.17M |
| 3 |
SV
Sturgeon Ventures
London,
United Kingdom
|
-$1.22M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$995K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$777K |
STXS Hedge Fund Activity: Q1 2022 in Review
93 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Stereotaxis (STXS) for Q1 2022, worth a combined $149M — down 43% from $263M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of STXS and 13 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 24 added.
The largest buyer was Lagoda Investment Management, adding an estimated $892K. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $2.56M sold.
- 93 institutional investors held Stereotaxis (STXS) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $149M of Stereotaxis stock for Q1 2022, down 43% quarter-over-quarter.
- 13 funds opened new Stereotaxis positions in Q1 2022 and 16 closed out, a net change of -3 holders.
- The largest Stereotaxis buyer in Q1 2022 was Lagoda Investment Management, an estimated $892K added.
- The largest Stereotaxis seller in Q1 2022 was Parkman Healthcare Partners, an estimated $2.56M sold.
Based on aggregated 13F filings for Q1 2022.